Department of Gastroenterology, Hepatology and Nutrition, Digestive Diseases and Surgery Institute, Cleveland Clinic, Cleveland, OH, USA.
Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA.
Indian J Gastroenterol. 2023 Oct;42(5):718-723. doi: 10.1007/s12664-023-01391-3. Epub 2023 Jul 31.
Studies report favorable efficacy and safety profiles of ustekinumab (UST) and vedolizumab (VDZ) in Crohn's disease (CD), but effectiveness and safety data in elderly patients with CD is lacking. We retrospectively analyzed 78 elderly patients (39 each UST and VDZ) and found that patients on UST and VDZ experienced similar rates of clinical response, remission and mucosal healing despite high proportion of prior biologic exposure. Both UST and VDZ appear to be effective and safe in this at-risk CD population. Further large studies are needed to validate our findings.
研究报告称乌司奴单抗（UST）和维得利珠单抗（VDZ）在克罗恩病（CD）中的疗效和安全性良好，但老年 CD 患者的有效性和安全性数据尚缺乏。我们回顾性分析了 78 例老年患者（UST 和 VDZ 各 39 例），发现尽管先前有大量生物制剂暴露，但 UST 和 VDZ 治疗的患者临床应答、缓解和黏膜愈合的比例相似。在这一高危 CD 人群中，UST 和 VDZ 均显示出有效性和安全性。需要进一步的大型研究来验证我们的发现。
